Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Undaunted, on Tuesday, Hims & Hers announced it is to offer branded versions of tirzepatide-- the molecule in the other FDA-approved obesity jab, Eli Lilly's Zepbound. It's also gearing up to sell ...

Eli Lilly says Indianapolis-based Premier Weight Loss is cracking open auto-injector pens containing its blockbuster drug and ...

Hims & Hers now provides access to Zepbound, a brand-name version of the drug tirzepatide, for $1,899 per month. HealthDay News — The telehealth company Hims & Hers Health is expanding its weight-loss ...

But with tirzepatide removed from the shortages list ... This development has already impacted the market, with shares of Hims & Hers Health, a company offering compounded versions of GLP-1 ...

4.6-star analyst Allen Lutz said that tirzepatide likely won’t bring in much money for Hims, especially since Eli Lilly sells it for $500 per month on its own platform, while Hims lists it at a ...

“We’ve now expanded that choice even further by adding access to generic liraglutide and branded tirzepatide through our platform,” the company said. Hims & Hers Health shares jumped Tuesday ...